Core Viewpoint - The article discusses Service Properties Trust (NASDAQ: SVC) and reflects on its previous rating of "Hold" due to concerns despite a high dividend yield of 9.69% [1]. Group 1 - The company has been previously analyzed over two years ago, with a focus on its dividend yield and financial stability [1]. - The author expresses a personal investment strategy aimed at achieving financial independence through dividend stocks, indicating a preference for steady income [1].

Industry Overview - Drug pricing has become a significant pressure point for pharmaceutical companies in the U.S. as efforts to reduce consumer costs at pharmacies intensify [1] - The U.S. is the largest single market for drugmakers, with prices often nearly three times higher than in other developed countries, leading to a heavy reliance on American sales for revenue [2] - The Most Favored Nations pricing model proposed by Donald Trump aims to tie U.S. drug prices to the lowest levels paid by other wealthy countries, which could have a substantial impact on pharmaceutical companies' financials if widely implemented [3][4] Market Performance - The S&P 500 Health Care sector has increased by over 13% this year, with health-care companies leading in earnings beats during the third quarter of 2025, marking the strongest performance in over four years [5] - Analysts suggest that as drug pricing uncertainty begins to ease, attention will shift to how pharmaceutical companies adapt to the changing landscape [5] Company Highlights Viatris Inc. (NASDAQ:VTRS) - Viatris has a dividend yield of 3.87% and is among the best dividend stocks in the pharmaceutical sector [11] - Barclays initiated coverage of Viatris with an Overweight rating and a $15 price target, noting improving investor sentiment and easing pricing pressure [12] - Viatris announced a deal to sell its equity stake in Biocon Biologics for $815 million, which includes $400 million in cash and $415 million in equity shares, aimed at enhancing its portfolio and market access [13] Gilead Sciences, Inc. (NASDAQ:GILD) - Gilead has a dividend yield of 2.54% and is recognized as a strong dividend stock [15] - The company entered a three-year agreement with the U.S. government to lower drug costs, reinforcing its commitment to U.S. innovation and affordability [16] - Gilead plans to invest $32 billion in U.S.-based manufacturing and R&D over the next five years, expecting to generate $43 billion in economic value and create over 3,000 jobs [17] Amgen Inc. (NASDAQ:AMGN) - Amgen has a dividend yield of 3.05% and has outperformed the broader market, with its stock up more than 27% since the start of 2025 [19] - The company reported a 12% revenue increase to $9.6 billion in the third quarter, driven by strong sales of key products like Repatha and Tezspire, both up 40% year-over-year [20] - Amgen has consistently raised its dividend since 2011, with a forward yield of about 3%, significantly higher than the S&P 500 average of 1.2% [22]

Core Viewpoint - Dividend investors seeking substantial gains should consider dividend stocks with a market capitalization below $10 billion [1] Group 1 - The focus is on dividend stocks that are not mainstream, providing an opportunity for higher returns [1] - Companies with a market cap under $10 billion may offer unique investment opportunities for dividend investors [1]

Core Viewpoint - Jim Cramer recommends three dividend stocks: Enbridge Inc., Pfizer, and Realty Income, highlighting their strong fundamentals and potential for long-term growth despite market volatility [1][2]. Enbridge Inc. - Enbridge is an oil pipeline company that focuses on the volume of oil transported rather than commodity prices, serving over 7 million U.S. customers [3][4]. - The company has a dividend yield of 5.98%, trading at $47.53, and is expected to add $8 billion in new projects next year, which could enhance cash flow and dividend payouts [5]. - Enbridge has raised its dividends for two consecutive years, paying an annual dividend of $2.84, and is considered to have a low-risk business model with strong fundamentals [5]. Pfizer Inc. - Pfizer is recognized as a dividend giant with a yield of 6.86%, viewed as a "bond equivalent" by Cramer, providing stable returns despite limited share price appreciation [6][7]. - The company has made strategic acquisitions, including Seagen and Metsera, to strengthen its drug pipeline and address patent expirations [7]. - Pfizer generated $14 billion in free cash flow this year, has a payout ratio of 53.13%, and has increased dividends for 15 consecutive years, with a 5-year dividend growth rate of 3.62% [8]. Realty Income - Realty Income is a REIT that leases commercial properties, offering a yield of 5.7% and known as 'The Monthly Dividend Company' [9][10]. - The company has a high occupancy rate of 98.7% and owns 15,500 single-tenant properties, demonstrating resilience even in weaker consumer spending environments [10][11]. - Realty Income has raised its dividend four times this year, pays an annual dividend of $3.24, and has a 4.2% annualized growth rate over the past three decades, making it a reliable high-yield dividend stock [10][11].

Market Performance - Major U.S. indexes ended the Christmas-shortened week higher, with the S&P 500 and Dow reaching new record highs, gaining 0.75% and 0.72% respectively, while the Nasdaq Composite increased by 0.70% [1] - The U.S. GDP growth rate for Q3 2025 was 4.3%, exceeding expectations and marking the fastest growth since Q3 2023 [2] - Despite a decline in consumer confidence, investor optimism is driven by strong corporate earnings outlook and AI enthusiasm [2] Stock Performance - Castle Biosciences, Inc. (CSTL) shares increased by 77.9% since being upgraded to a Zacks Rank 1 (Strong Buy) on October 20, significantly outperforming the S&P 500's 3.8% increase [3][6] - F.N.B. Corporation (FNB) shares rose by 13.4% after its upgrade to Zacks Rank 2 (Buy) on October 21, compared to the S&P 500's 2.8% increase [4] - Hamilton Insurance Group, Ltd. (HG) and Kinross Gold Corporation (KGC) saw gains of 19.8% and 7.7% respectively since their upgrade to Outperform on October 17 [7] Portfolio Performance - A hypothetical portfolio of Zacks Rank 1 stocks returned +14.3% in 2025, slightly underperforming the S&P 500's +14.9% [11] - The Zacks Model Portfolio has outperformed the S&P 500 index by over 12 percentage points since 1988, with an annualized average return of +23.9% compared to +11.5% for the S&P 500 [13] - The Zacks Earnings Certain Admiral Portfolio (ECAP) returned -1.30% in Q3 2025, underperforming the S&P 500's +8.1% gain [15] Dividend Portfolio Performance - Johnson & Johnson (JNJ) returned 14.3% over the past 12 weeks, while 3M Company (MMM) increased by 5.2% during the same period [18] - The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -0.01% in Q3 2025, compared to the S&P 500's +8.1% gain [19]

Core Viewpoint - British American Tobacco (BTI) is experiencing a divergence in analyst outlook, with Morgan Stanley maintaining a cautious stance while Jefferies expresses strong confidence in the company's growth potential, particularly in smoke-free products [2][3]. Analyst Ratings and Price Targets - Morgan Stanley analyst Rashad Kawan raised the price target for BTI to 3,050 GBp from 3,000 GBp but retained an Underweight rating on the shares [2]. - Jefferies has named BTI as its top pick in the global tobacco sector, citing a sustainable shift towards a smoke-free product portfolio that is not fully reflected in the current share price [3]. Investment Case Factors - Jefferies analyst Andrei Andon-Ionita highlighted several positive factors for BTI, including market share gains in the US modern oral segment, early signs of volume and pricing improvements, and a solid outlook for combustibles through 2026 [4]. - The company's strong balance sheet is expected to allow for continued and meaningful cash returns to shareholders [4]. Growth in Modern Oral Products - Jefferies is more optimistic than the broader Wall Street consensus regarding BTI's growth in modern oral products, particularly in the US, where Velo Plus has seen over 300% growth in both volume and value [5]. - The resilience of the combustibles business is noted, as it continues to generate robust cash flow and margin expansion despite ongoing volume declines [5].

Group 1: Company Developments - Nutrien Ltd. has streamlined its portfolio by selling its 50% equity stake in Argentina-based nitrogen producer Profertil S.A. for approximately $600 million in pre-tax proceeds [3] - The company has generated roughly $900 million in gross proceeds from asset sales since Q4 2024, indicating a broader divestment strategy to enhance focus and strengthen its balance sheet [4] - Nutrien's President and CEO, Ken Seitz, emphasized that the sale of Profertil is part of efforts to simplify the portfolio, improve earnings quality, and enhance cash conversion [4] Group 2: Market Outlook - Mizuho raised its price target on Nutrien to $65 from $61 while maintaining a Neutral rating, reflecting ongoing pressures in the chemicals, agriculture, and packaging sector [2] - The analyst noted that higher export volumes from China are impacting basic chemical markets, and a weak start to the March quarter is anticipated following a weak December quarter for many companies in the sector [2] Group 3: Business Operations - Nutrien operates as a global supplier of essential crop nutrients, producing and distributing potash, nitrogen, and phosphate [4] - The company supports farmers through its retail platform, Nutrien Ag Solutions, which offers products, services, and agronomic expertise across key agricultural regions [4]

Core Viewpoint - The Toronto-Dominion Bank (TD) is recognized as a strong investment opportunity, particularly due to its recent dividend increase and positive earnings outlook despite challenges in the operating environment [1][4]. Group 1: Dividend and Earnings Performance - On December 4, TD announced a 3% increase in its quarterly dividend to C$1.08 per share, reflecting management's confidence in the bank's growth and earnings potential [3][5]. - TD's earnings have improved, driven by stronger capital markets activity and solid volume growth in Canadian banking, with an expectation of adjusted earnings per share growth between 6% and 8% in fiscal 2026 [4]. Group 2: Analyst Upgrades and Market Position - National Bank analyst Gabriel Dechaine upgraded TD to Outperform from Sector Perform, setting a price target of C$134 [2]. - TD maintains a capital position well above regulatory minimums, which is a positive indicator of its financial health [4]. Group 3: Management and Strategic Focus - Raymond Chun, the new president and CEO, is focused on cutting expenses and enhancing anti-money-laundering controls following a historic settlement with US authorities [5]. - The bank offers a diverse range of products and services, including investing, mortgages, everyday banking, and small business solutions, supported by its online banking platform [6].

Core Viewpoint - York Water is recognized for its long-standing commitment to shareholder dividends, having made 620 consecutive payments over more than two centuries, making it a reliable choice for dividend investors [1][2]. Company Overview: York Water - York Water is the oldest investor-owned water utility in the United States, providing water and wastewater treatment services primarily in southern and central Pennsylvania [4]. - The company generates approximately 64% of its operating revenue from residential customers and 29% from commercial and industrial customers in 2024 [4]. - As a regulated utility, York Water files rate increase requests with the Pennsylvania Public Utility Commission, ensuring steady cash flows to support its dividend payments [6]. Key Financial Metrics: York Water - Current Price: $32.44 [5] - Market Cap: $468 million [5] - Gross Margin: 55.27% [6] - Dividend Yield: 2.70% [6] Company Overview: American States Water - American States Water operates primarily in California and relies on regulated businesses for the majority of its earnings, with its regulated water business contributing 79.2% to its consolidated earnings per share (EPS) of $3.17 in 2024 [8][9]. - The company has a history of 71 consecutive years of raising its dividend, placing it among the elite Dividend Kings [10][12]. Key Financial Metrics: American States Water - Current Price: $73.04 [7] - Market Cap: $2.8 billion [7] - Gross Margin: 51.96% [8] - Dividend Yield: 2.65% [8] Comparative Performance - Over the past 20 years, American States Water has delivered a better total return compared to York Water, highlighting its strong commitment to increasing dividends [11].

Core Viewpoint - Global dividend stocks are gaining attention as global dividends reached a record $1.75 trillion in 2024, reflecting a 6.6% underlying growth, with 17 out of 49 tracked countries paying record dividends [2][3]. Global Dividend Market - The growth in global dividends is broad-based, with significant contributions from countries like the US, Canada, France, Japan, and China [3]. - Approximately 88% of firms worldwide either increased or maintained their dividend payouts during the year, indicating strong consistency for long-term investors [3]. UK Dividend Market - The UK has seen a slower recovery in dividend growth, with expectations for 2026 to deliver a record £86 billion in FTSE 100 dividends, up from £80.7 billion forecasted for 2025 [4]. - The FTSE 100 is projected to offer a forward dividend yield of about 3.2% in 2025 and 3.4% in 2026, which remains above the S&P 500's dividend yield [5]. Pembina Pipeline Corporation - Pembina Pipeline Corporation has a dividend yield of 5.47% and reported adjusted EBITDA of $1.03 billion in Q3 2025, showing a modest year-over-year increase [10][12]. - The company’s adjusted cash flow from operating activities reached $648 million in the quarter, covering dividend payments effectively [13]. - Pembina operates one of the largest energy transportation and midstream networks in Canada, moving crude oil, natural gas, and natural gas liquids [14]. NatWest Group plc - NatWest Group plc has a dividend yield of 3.67% and reported a profit before tax of £2.18 billion in Q3 2025, a 30.4% year-over-year increase [15][17]. - The bank's non-interest income climbed 25.9% to £0.91 billion, while net interest income grew 12.7% to £3.09 billion, indicating a shift towards fee-based businesses [18]. - NatWest has implemented structural hedges to protect lending margins, extending its position into 2027, which may lead to industry-leading margins [19]. Bank of Montreal - Bank of Montreal has a dividend yield of 3.66% and reported a significant increase in profit driven by a rebound in dealmaking and stronger equity markets [21][22]. - The capital markets unit's profit more than doubled to C$521 million, supported by higher revenue from global market activity [23]. - Provision for credit losses fell to C$755 million from C$1.52 billion the previous year, indicating improved confidence in credit quality [24].